10x Genomics Management
Management criteria checks 3/4
10x Genomics' CEO is Serge Saxonov, appointed in Jul 2012, has a tenure of 13.08 years. total yearly compensation is $7.93M, comprised of 7.9% salary and 92.1% bonuses, including company stock and options. directly owns 3.3% of the company’s shares, worth $57.52M. The average tenure of the management team and the board of directors is 3.6 years and 6.2 years respectively.
Key information
Serge Saxonov
Chief executive officer
US$7.9m
Total compensation
| CEO salary percentage | 7.89% |
| CEO tenure | 13.1yrs |
| CEO ownership | 3.3% |
| Management average tenure | 3.6yrs |
| Board average tenure | 6.2yrs |
Recent management updates
Recent updates
10x Genomics: Stuck In Neutral
Jun 23Revenues Not Telling The Story For 10x Genomics, Inc. (NASDAQ:TXG) After Shares Rise 31%
Jun 20
Shareholders May Be Wary Of Increasing 10x Genomics, Inc.'s (NASDAQ:TXG) CEO Compensation Package
May 27Earnings Release: Here's Why Analysts Cut Their 10x Genomics, Inc. (NASDAQ:TXG) Price Target To US$12.96
May 14Positive Sentiment Still Eludes 10x Genomics, Inc. (NASDAQ:TXG) Following 29% Share Price Slump
Apr 11We Think 10x Genomics (NASDAQ:TXG) Can Easily Afford To Drive Business Growth
Mar 26
Chan Zuckerberg Initiative Partnership Will Drive Future Demand
Strategic introduction of lower-priced products and sales reorganization are poised to drive volume growth and enhance market share in biopharma and academia.10x Genomics, Inc. (NASDAQ:TXG) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Feb 2110x Genomics: Struggling Amid Operational Challenges
Jan 06Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts
Nov 0110x Genomics: Deciphering The Preliminary Q3 Earnings
Oct 12The Price Is Right For 10x Genomics, Inc. (NASDAQ:TXG) Even After Diving 28%
Oct 1110x Genomics Is Still A Long Way From Profitability
Oct 03We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow
Sep 09Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump
Aug 1010x Genomics Stock Slips As Illumina Snaps Up Competitor - Tough Times Ahead
Jul 1010x Genomics: Sticking To The Plan To Avoid The Falling The Knife
Jun 21Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper
Jun 1410x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business
May 21Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price
Apr 15Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Feb 0510x Genomics: Sales Are Growing At A Rapid Rate, But So Are Expenses
Jan 20Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%
Dec 22We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely
Nov 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -US$85m |
| Mar 31 2025 | n/a | n/a | -US$157m |
| Dec 31 2024 | US$8m | US$625k | -US$183m |
| Sep 30 2024 | n/a | n/a | -US$183m |
| Jun 30 2024 | n/a | n/a | -US$240m |
| Mar 31 2024 | n/a | n/a | -US$264m |
| Dec 31 2023 | US$8m | US$545k | -US$255m |
| Sep 30 2023 | n/a | n/a | -US$223m |
| Jun 30 2023 | n/a | n/a | -US$172m |
| Mar 31 2023 | n/a | n/a | -US$174m |
| Dec 31 2022 | US$19m | US$504k | -US$166m |
| Sep 30 2022 | n/a | n/a | -US$167m |
| Jun 30 2022 | n/a | n/a | -US$142m |
| Mar 31 2022 | n/a | n/a | -US$89m |
| Dec 31 2021 | US$12m | US$430k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$455m |
| Jun 30 2021 | n/a | n/a | -US$504m |
| Mar 31 2021 | n/a | n/a | -US$533m |
| Dec 31 2020 | US$11m | US$400k | -US$543m |
| Sep 30 2020 | n/a | n/a | -US$134m |
| Jun 30 2020 | n/a | n/a | -US$78m |
| Mar 31 2020 | n/a | n/a | -US$49m |
| Dec 31 2019 | US$2m | US$394k | -US$31m |
| Sep 30 2019 | n/a | n/a | -US$100m |
| Jun 30 2019 | n/a | n/a | -US$105m |
| Mar 31 2019 | n/a | n/a | -US$105m |
| Dec 31 2018 | US$1m | US$366k | -US$112m |
Compensation vs Market: Serge's total compensation ($USD7.93M) is above average for companies of similar size in the US market ($USD5.76M).
Compensation vs Earnings: Serge's compensation has been consistent with company performance over the past year.
CEO
Serge Saxonov (48 yo)
Dr. Serge Saxonov, Ph D, Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at Quanta...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 13.1yrs | US$7.93m | 3.3% $ 57.5m | |
| Co-Founder | 13.1yrs | US$4.27m | 2.6% $ 45.4m | |
| CFO, Treasurer | 1yr | US$3.60m | 0.077% $ 1.3m | |
| Chief Legal Officer | 8.1yrs | US$7.00m | 0.14% $ 2.4m | |
| Chief of Global Operations | 1.6yrs | no data | no data | |
| Founding Scientist & CTO | 3.6yrs | no data | no data | |
| Manager of Investor Relations & Strategic Finance | no data | no data | no data | |
| Chief Commercial Officer | 1yr | no data | no data | |
| Associate Director of Product Management | no data | no data | no data |
Experienced Management: TXG's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 13.1yrs | US$7.93m | 3.3% $ 57.5m | |
| Co-Founder | 13.1yrs | US$4.27m | 2.6% $ 45.4m | |
| Independent Director | 5.4yrs | US$258.05k | 0.011% $ 185.9k | |
| Independent Chairman | 12yrs | US$318.30k | 1.97% $ 34.3m | |
| Independent Director | 6yrs | US$251.76k | 0.011% $ 185.9k | |
| Independent Director | 1.2yrs | US$477.99k | 0.032% $ 560.8k | |
| Independent Director | 6.3yrs | US$263.46k | 0.034% $ 587.8k | |
| Independent Director | 1.1yrs | US$469.85k | no data |
Experienced Board: TXG's board of directors are considered experienced (6.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/28 13:54 |
| End of Day Share Price | 2025/08/28 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
10x Genomics, Inc. is covered by 22 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |
| Kyle Mikson | Canaccord Genuity |